About IDIS Pharma
Idis was founded in 1987 in Weybridge, United Kingdom, within the pharmaceutical sector. Unlicensed medicines and medical products are provided to patients facing unmet medical needs. The Named Patient Program was introduced in 1993 to assist pharmaceutical and biotechnology industries. Services are extended to patients, pharmacists, physicians, and pharmaceutical companies through these operations.
- Headquarter Weybridge, United Kingdom
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of IDIS Pharma
Detailed funding history for IDIS Pharma
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in IDIS Pharma
IDIS Pharma has secured backing from 1 investor. Prominent investors backing the company include Clinigen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Specialty medicines are supplied via clinical trials and access programs.
|
Locked | Locked | Locked |
Investor details for IDIS Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IDIS Pharma
Investment portfolio details for IDIS Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IDIS Pharma
Detailed financials for IDIS Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Idis Pharma Comparisons
Peer comparison for IDIS Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IDIS Pharma
Detailed competitors of IDIS Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Idis Pharma
Complete news archive for IDIS Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IDIS Pharma
IDIS Pharma was founded in 1987.
IDIS Pharma is headquartered in Weybridge, United Kingdom.
Idis was founded in 1987 in Weybridge, United Kingdom, within the pharmaceutical sector. Unlicensed medicines and medical products are provided to patients facing unmet medical needs. The Named Patient Program was introduced in 1993 to assist pharmaceutical and biotechnology industries. Services are extended to patients, pharmacists, physicians, and pharmaceutical companies through these operations.
IDIS Pharma has 1 investor. Key investors include Clinigen.